Deals
Takeda May Sell Shire Pipeline Drug to Clear EU Antitrust Review
This article is for subscribers only.
Takeda Pharmaceutical Co. is in talks with European antitrust regulators about selling an experimental inflammatory bowel disease drug to help close its $62 billion takeover of Shire Plc.
In a statement released Friday, Takeda said that it has been in discussions with the European Commission about divesting SHP647, which is in the final stages of experimental testing for the treatment of two gastrointestinal disorders: Crohn’s disease and ulcerative colitis.